Orencia® (abatacept) 125mg solution for injection - New Formulation

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates> SPC Changes Bristol-Myers Squibb has been granted marketing authorisation for a new formulation given by subcutaneous injection.   Orencia® (abatacept) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a tumour necrosis factor-alpha inhibitor.   Please see link to SPC for full prescribing information.
Source: NeLM - SPC Changes - Category: Drugs & Pharmacology Source Type: news

Related Links:

Authors: Hur K, Jearn H, Kim TY PMID: 30430789 [PubMed - in process]
Source: Annals of Laboratory Medicine - Category: Laboratory Medicine Tags: Ann Lab Med Source Type: research
Serum PGLYRP‑1 is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis. Mol Med Rep. 2018 Nov 08;: Authors: Luo Q, Li X, Zhang L, Yao F, Deng Z, Qing C, Su R, Xu J, Guo Y, Huang Z, Li J Abstract Peptidoglycan recognition protein‑1 (PGLYRP‑1) is a part of the innate immune system. It is well‑known that dysregulation of innate immune responses is present in patients with rheumatoid arthritis (RA). However, the role of Pglyrp1/PGLYPR‑1 in RA is poorly understood. Reverse transcription‑quantitative polymerase chain reaction was used to detect the level of Pglyrp1 in perip...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Condition:   Rheumatoid Arthritis Intervention:   Other: pharmaceutical care services Sponsor:   hager omar mohammed siddik Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: Overcorrection of angle at fusion segments requiring O-C7 angle change was a risk factor for late subaxial lesion in patients with RA with fragile bones and joints. Correction should be limited, considering the residual mobility of the cervical unfixed segments. PMID: 30424593 [PubMed - as supplied by publisher]
Source: Asian Spine Journal - Category: Orthopaedics Tags: Asian Spine J Source Type: research
Contributors : Navin Varadarajan ; Ankit MahendraSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAlthough the contribution of B-cell derived autoreactive antibodies to rheumatoid arthritis (RA) has been studied extensively, the autoantibody-independent roles of B cells in the progression of the disease is not well-defined. By utilizing whole transcriptome profiling of human citrulline-specific B cells, we identified diverse inflammatory pathways, cytokines and transcriptional programs that define the biological role of B cells in RA and identify targets for drug intervention. Signific...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
(Natural News) Rheumatoid arthritis is a debilitating disease that causes the joints, usually in the hands, to become inflamed and painful. It usually affects older individuals, although people as young as 30 can suffer from the disease. Like most autoimmune diseases, there is no cure for rheumatoid arthritis, but effectively managing it begins with eating...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
AbstractBiologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians ’ armamentaria in the combat against these medical conditions. Yet they are extremely expensive, costing on average $10,000–$30,000 per year and exceed $500,000 for the most expensive biologics. The advent of biosimilar drugs, or high similar copies of biologics, was supposed to help reduce cost s, but thus far the cost of trea...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
AbstractAnkylosing spondylitis, multiple sclerosis, rheumatoid arthritis and rheumatic fever are autoimmune inflammatory diseases that may be triggered in genetically susceptible individuals by specific bacterial pathogens. Inhibiting the growth of these bacteria with high antioxidant plant extracts may inhibit the aetiology of these diseases, as well as inhibiting the later phase symptoms.P. squarrosa extracts were analysed for antioxidant activity using a DPPH free radical scavenging assay. Bacterial growth inhibitory activity was evaluated using disc diffusion assays and the activity was quantified by MIC determination....
Source: Inflammopharmacology - Category: Drugs & Pharmacology Source Type: research
This study assessed the efficacy and safety of tofacitinib in Chinese patients with RA enrolled in Phase 3 and long-term extension (LTE) studies. Methods: ORAL Sync was a 1-year, randomized, placebo-controlled, Phase 3 trial. Patients received tofacitinib 5 or 10 mg twice daily (BID) or placebo advanced to tofacitinib 5 or 10 mg BID at 3 or 6 months. All patients remained on ≥1 background conventional synthetic disease-modifying antirheumatic drug. ORAL Sequel is an open-label LTE study (data-cut: March 2015; data collection and analyses were ongoing, and study database was not locked at the time of analysis; study...
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
Publication date: December 2018Source: Joint Bone Spine, Volume 85, Issue 6Author(s): Bruno FautrelAbstractOnce remission or low disease activity (LDA) is attained in established rheumatoid arthritis (RA) patients, attempting disease-modifying anti-rheumatic drug (DMARD) tapering appears to be a viable option to avoid patient overtreatment. Potential benefits include reduction in the treatment burden and the risk of adverse events, although the latter has not been demonstrated convincingly. The feasibility of DMARD discontinuation has been tested in numerous studies or trials. All have revealed a high risk of relapse, rang...
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
More News: Abatacept | Arthritis | Databases & Libraries | Drugs & Pharmacology | Marketing | Methotrexate | Orencia | Rheumatoid Arthritis | Rheumatology